1 / 5

ARZU DIDEM YALCIN, MD. Department of Internal Medicine, Allergy and Clinical Immunology Unit .

I ncreased serum sTRAIL level in newly diagnosed stage -IV lung adenocarcinoma but not squamous cell carcinoma , is correlated with age and smoking. ARZU DIDEM YALCIN, MD. Department of Internal Medicine, Allergy and Clinical Immunology Unit . XXI World Congress of Asthma

eilis
Télécharger la présentation

ARZU DIDEM YALCIN, MD. Department of Internal Medicine, Allergy and Clinical Immunology Unit .

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Increased serum sTRAIL level in newlydiagnosedstage-IV lungadenocarcinoma but not squamouscellcarcinoma, is correlatedwithageandsmoking ARZU DIDEM YALCIN, MD. Department of Internal Medicine, Allergy and Clinical Immunology Unit. XXI World Congress of Asthma Interasma Global Assosiation August 21, Room B, 12.30-14.15 Oral presentation 89 QUEBEC/CANADA

  2. BACKGROUND • Lung cancer is the leading cause of cancer mortality in the world. • Many factors can protect against or facilitate the development of the cancer. • A TNF family member TRAIL, has a complex physiological role beyond that of merely activating the apoptotic pathway in cancer cells. • Vitamin D is converted to its active form locally in the lung, and is also thought to play an important role in lung health. Our goal was to investigate the possible clinical significance of serum sTRAIL and 1,25-dihydroxyvitamin D(3) levels in patients with non-small cell lung cancer (NSCLC).

  3. OBJECTIVE • Our goal was to investigate the possible clinical significance of serum sTRAIL and 1,25-dihydroxyvitamin D(3) levels in patients with non-small cell lung cancer (NSCLC).

  4. METHODS • 18 consecutive adenocarcinoma and 22 squamous cell carcinoma patients with stage-IV non-small cell lung cancer • 12 men and 6 women, with ages ranging from 38 to 97 (mean 60.5) years with adenocarcinoma, • 20 men and 2 women, with ages ranging from 46 to 80 (mean 65) years with squamous cell carcinoma.

  5. Institutions • ATIL:LinköpingUniversity, Linköping, Sweden • AYSEGUL:Denizli Training and Research Hospital, Antalya, Turkey • REG:University Health Network, Toronto, Canada

More Related